1-2 of 2
Agnès Guerci, MD, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Study of Post–Remission Therapy with Azacitidine (AZA) in Patients with AML Post-MDS and High-Risk MDS: A GFM Group Study.

Claude Gardin, MD, Thomas Prébet, MD, Krimo Bouabdallah, MD, Denis Caillot, MD, Agnès Guerci, MD, PhD, Emmanuel Raffoux, MD, Jean Pierre Marolleau, MD, Cecile Pautas, MD, Anne Banos, MD, Chantal Himberlin, MD, Anne-Laure Taksin, MD, Arnaud Pigneux, MD, PhD, Xavier Thomas, MD, PhD, Tony Jernival, Norbert Vey, Francois Dreyfus, MD, PhD, Sylvie Chevret, PhD, Herve Dombret, MD, PhD, Pierre Fenaux
Journal: Blood
Blood (2009) 114 (22): 844.
https://doi.org/10.1182/blood.V114.22.844.844
Published: 2009
Journal Articles

Significant Higher Rates of Undetectable Molecular Residual Disease and Molecular Responses with Pegylated Form of Interferon a2a in Combination with Imatinib (IM) for the Treatment of Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukaemia (CML) Patients (pts): Confirmatory Results at 18 Months of Part 1 of the Spirit Phase III Randomized Trial of the French CML Group (FI LMC).

François Guilhot, MD, Claude Preudhomme, Joelle Guilhot, MSci, Francois-Xavier Mahon, MD, PhD, Franck Emmanuel Nicolini, MD, PhD, Francoise Rigual-Huguet, MD, Laurence Legros, MD, PhD, Agnès Guerci, MD, PhD, Delphine Rea, MD, PhD, Valerie Coiteux, MD, Frederic Maloisel, MD, Martine Gardembas, MD, Claude-Eric Bulabois, MD, Marc G Berger, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 340.
https://doi.org/10.1182/blood.V114.22.340.340
Published: 2009